ArticleHaematologica2015
Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.
Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Picalm coordinates clathrin-mediated endocytosis and actin remodeling during myogenesis.Molecular metabolism · 2026Article
- PICALM::MLLT10 translocated leukemia.FEBS letters · 2026Review
- Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026Review
- A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression.Experimental hematology & oncology · 2025Article
- Picalm, a novel regulator of GLUT4-trafficking in adipose tissue.Molecular metabolism · 2024Article
- Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier.Molecular neurodegeneration · 2023Article
- Review
- CircCLTH promotes skeletal muscle development and regeneration.Epigenetics · 2022Article
- Selective endocytosis of CaScience advances · 2022Article
- Endocytosis of the thrombopoietin receptor Mpl regulates megakaryocyte and erythroid maturation in mice.Frontiers in oncology · 2022Article
- CALM supports clathrin-coated vesicle completion upon membrane tension increase.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Creation of a functionalmicroPublication biology · 2021Article
- Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.American journal of human genetics · 2021Article
- Successful treatment of T/myeloid mixed-phenotype acute leukemia with the translocation (10;11)(p13;q14)Clinical case reports · 2021Article
- Multiorgan failure with abnormal receptor metabolism in mice mimicking Samd9/9L syndromes.The Journal of clinical investigation · 2021Article
- Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- Endocytic Adaptor Proteins in Health and Disease: Lessons from Model Organisms and Human Mutations.Cells · 2019Review
- Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1.Experimental hematology · 2019Article
- Redundant and nonredundant organismal functions of EPS15 and EPS15L1.Life science alliance · 2019Article
- Computational analysis of functional SNPs in Alzheimer's disease-associated endocytosis genes.PeerJ · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
Clathrin-dependent endocytosis is an essential cellular process shared by all cell types. Despite this, precisely how endocytosis is regulated in a cell-type-specific manner and how this key pathway functions physiologically or pathophysiologically remain largely unknown. PICALM, which encodes the clathrin adaptor protein PICALM, was originally identified as a component of the CALM/AF10 leukemia oncogene. Here we show, by employing a series of conditional Picalm knockout mice, that PICALM critically regulates transferrin uptake in erythroid cells by functioning as a cell-type-specific regulator of transferrin receptor endocytosis. While transferrin receptor is essential for the development of all hematopoietic lineages, Picalm was dispensable for myeloid and B-lymphoid development. Furthermore, global Picalm inactivation in adult mice did not cause gross defects in mouse fitness, except for anemia and a coat color change. Freeze-etch electron microscopy of primary erythroblasts and live-cell imaging of murine embryonic fibroblasts revealed that Picalm function is required for efficient clathrin coat maturation. We showed that the PICALM PIP2 binding domain is necessary for transferrin receptor endocytosis in erythroblasts and absolutely essential for erythroid development from mouse hematopoietic stem/progenitor cells in an erythroid culture system. We further showed that Picalm deletion entirely abrogated the disease phenotype in a Jak2(V617F) knock-in murine model of polycythemia vera. Our findings provide new insights into the regulation of cell-type-specific transferrin receptor endocytosis in vivo. They also suggest a new strategy to block cellular uptake of transferrin-bound iron, with therapeutic potential for disorders characterized by inappropriate red blood cell production, such as polycythemia vera.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.